a Department of Pharmacology, University of Cambridge , Cambridge , UK.
b IOTA Pharmaceuticals Ltd , St Johns Innovation Centre , Cambridge CB4 0WS , UK.
Expert Opin Ther Pat. 2018 Jul;28(7):573-590. doi: 10.1080/13543776.2018.1494155. Epub 2018 Jul 9.
Glioblastoma multiforme (GBM) is the most common and aggressive malignant glioma, with patients having a median survival of just over one year. Current chemotherapies, with surgery and radiotherapy, provide only minor patient benefit. There is a great need to discover and develop novel therapies for this devastating disease. Areas covered: Expert opinion:
The patent literature reveals novel therapies, providing insights into emerging GBM therapeutics. We have used the Google and USPTO patent databases to generate a detailed landscape of patents and patent applications from companies active in the areas of glioma and/or GBM. Specific patents have been grouped into six areas: novel compounds; treatments and therapeutic targets; combination therapies; immunotherapies; delivery methods; and biomarkers for diagnosis and prognosis.
There has been a steady increase in the number of patents on GBM over the last five years. Despite many new compounds being developed and patented for a broad range of cancers, only a small percentage of these are specifically targeted to GBM. Notable trends in the patent literature include both the development of combination therapies to combat the heterogeneous nature of GBM, and the use of immunotherapies building on the promise of cancer vaccines and CAR T-cell therapy.
多形性胶质母细胞瘤（GBM）是最常见和侵袭性最强的恶性胶质瘤，患者的中位生存期仅超过一年。目前的化疗、手术和放疗仅能为患者带来微小的益处。因此，非常有必要为这种毁灭性疾病发现和开发新的治疗方法。
专家意见：
专利文献揭示了新的治疗方法，为新兴的 GBM 治疗方法提供了新的见解。我们使用谷歌和美国专利商标局的专利数据库，生成了一份来自积极从事神经胶质瘤和/或 GBM 领域的公司的专利和专利申请的详细全景图。具体专利分为六个领域：新型化合物；治疗和治疗靶点；联合治疗；免疫疗法；给药方法；以及用于诊断和预后的生物标志物。
在过去五年中，GBM 的专利数量稳步增加。尽管针对广泛的癌症开发和获得了许多新的化合物专利，但只有一小部分专门针对 GBM。专利文献中的显著趋势包括开发联合疗法以应对 GBM 的异质性，以及利用癌症疫苗和 CAR T 细胞疗法的潜力来开发免疫疗法。
